A Phase 1b Study to Assess the Safety, Tolerability, and Efficacy of TAS-120 (Futibatinib) in Combination with MK-3475 (Pembrolizumab) in Patients with Solid Tumors (MK3475 - 990)
Latest Information Update: 01 Nov 2022
At a glance
- Drugs Futibatinib (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.; Taiho Pharmaceutical
- 13 Sep 2022 Results (n=30; as of 29 Nov 2021) from feasibility phase and expansion phase (cohort A and Cohort B) reporting safety and tolerability of futibatinib plus pembrolizumab in patients with advanced or metastatic solid tumors and first results for preliminary antitumor activity in patients with esophageal carcinoma presented at the 47th European Society for Medical Oncology Congress
- 05 Aug 2022 Planned number of patients changed from 133 to 273.
- 05 Aug 2022 Planned End Date changed from 30 Jun 2023 to 31 May 2024.